Lifetime exposure to estrogens and Parkinson's disease in California teachers

Parkinsonism and Related Disorders

Volumn 20, Issue 11, 2014, Pages 1149-1156

  Gatto, N M ^a   Deapen, D ^d   Stoyanoff, S ^d   Pinder, R ^d   Narayan, S ^b   Bordelon, Y ^c   Ritz, B ^b,c  

^a LOMA LINDA UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Estrogen; Hormone therapy; Menopause; Parkinson's; Reproductive

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST FEEDING; CAUCASIAN; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ESTROGEN THERAPY; FEMALE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; PARITY; PARKINSON DISEASE; POPULATION EXPOSURE; REPRODUCTIVE HEALTH; RISK ASSESSMENT; RISK REDUCTION; TEACHER; UNITED STATES; WOMEN'S HEALTH; AGE; MIDDLE AGED; REGRESSION ANALYSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNIVERSITY;

ADULT; AGE FACTORS; CALIFORNIA; COHORT STUDIES; ESTROGENS; FACULTY; FEMALE; HUMANS; MIDDLE AGED; PARKINSON DISEASE; REGRESSION ANALYSIS; RISK FACTORS;

EID: 84908604591     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2014.08.003     Document Type: Article

References (33)

1. Kurtzke J.F., Goldberg I.D. Parkinsonism death rates by race, sex, and geography. Neurology 1988, 38(10):1558-1561.
2. Callier S., Le Saux M., Lhiaubet A.M., Di Paolo T., Rostene W., Pelaprat D. Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion (Mpp+) towards dopaminergic mesencephalic neurones in primary culture. J Neurochem 2002, 80(2):307-316.
3. Disshon K.A., Boja J.W., Dluzen D.E. Inhibition of striatal dopamine transporter activity by 17beta-estradiol. Eur J Pharmacol 1998, 345(2):207-211.
4. Ascherio A., Weisskopf M.G., O'Reilly E.J., McCullough M.L., Calle E.E., Rodriguez C., et al. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol 2004, 160(10):977-984.
5. Benedetti M.D., Maraganore D.M., Bower J.H., McDonnell S.K., Peterson B.J., Ahlskog J.E., et al. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov Disord 2001, 16(5):830-837.
6. Currie L.J., Harrison M.B., Trugman J.M., Bennett J.P., Wooten G.F. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004, 61(6):886-888.
7. Frigerio R., Breteler M.M., de Lau L.M., Sanft K.R., Bower J.H., Ahlskog J.E., et al. Number of children and risk of Parkinson's disease. Mov Disord 2007, 22(5):632-639.
8. Nicoletti A., Nicoletti G., Arabia G., Annesi G., De Mari M., Lamberti P., et al. Reproductive factors and Parkinson's disease: a multicenter case-control study. Mov Disord 2011, 26(14):2563-2566.
9. Popat R.A., Van Den Eeden S.K., Tanner C.M., McGuire V., Bernstein A.L., Bloch D.A., et al. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005, 65(3):383-390.
10. Ragonese P., D'Amelio M., Salemi G., Aridon P., Gammino M., Epifanio A., et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 2004, 62(11):2010-2014.
11. Rugbjerg K., Christensen J., Tjonneland A., Olsen J.H. Exposure to estrogen and women's risk for Parkinson's disease: a prospective cohort study in Denmark. Parkinsonism Relat Disord 2013, 19(4):457-460.
12. Simon K.C., Chen H., Gao X., Schwarzschild M.A., Ascherio A. Reproductive factors, exogenous estrogen use, and risk of Parkinson's disease. Mov Disord 2009, 24(9):1359-1365.
13. Bernstein L., Allen M., Anton-Culver H., Deapen D., Horn-Ross P.L., Peel D., et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002, 13(7):625-635.
14. Gelb D.J., Oliver E., Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999, 56(1):33-39.
15. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992, 55(3):181-184.
16. Foltynie T., Matthews F.E., Ishihara L., Brayne C. The frequency and validity of self-reported diagnosis of Parkinson's Disease in the UK elderly: MRC CFAS cohort. BMC Neurol 2006, 6:29.
17. Bernstein L., Pike M.C., Ross R.K., Henderson B.E. Age at menarche and estrogen concentrations of adult women. Cancer Causes Control 1991, 2(4):221-225.
18. Chavez-MacGregor M., van Gils C.H., van der Schouw Y.T., Monninkhof E., van Noord P.A., Peeters P.H. Lifetime cumulative number of menstrual cycles and serum sex hormone levels in postmenopausal women. Breast Cancer Res Treat 2008, 108(1):101-112.
19. Fortner R.T., Hankinson S.E., Schairer C., Xu X., Ziegler R.G., Eliassen A.H. Association between reproductive factors and urinary estrogens and estrogen metabolites in premenopausal women. Cancer Epidemiol Biomarkers Prev 2012, 21(6):959-968.
20. Windham G.C., Elkin E., Fenster L., Waller K., Anderson M., Mitchell P.R., et al. Ovarian hormones in premenopausal women: variation by demographic, reproductive and menstrual cycle characteristics. Epidemiology 2002, 13(6):675-684.
21. Dorgan J.F., Reichman M.E., Judd J.T., Brown C., Longcope C., Schatzkin A., et al. Relationships of age and reproductive characteristics with plasma estrogens and androgens in premenopausal women. Cancer Epidemiol Biomarkers Prev 1995, 4(4):381-386.
22. Ragonese P., D'Amelio M., Callari G., Salemi G., Morgante L., Savettieri G. Age at menopause predicts age at onset of Parkinson's disease. Mov Disord 2006, 21(12):2211-2214.
23. Rocca W.A., Bower J.H., Maraganore D.M., Ahlskog J.E., Grossardt B.R., de Andrade M., et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008, 70(3):200-209.
24. Islam M.S., Protic O., Stortoni P., Grechi G., Lamanna P., Petraglia F., et al. Complex networks of multiple factors in the pathogenesis of uterine leiomyoma. Fertil Steril 2013, 100(1):178-193.
25. Liao P.V., Dollin J. Half a century of the oral contraceptive pill: historical review and view to the future. Can Fam Physician 2012, 58(12):e757-e760.
26. Hoover R., Bain C., Cole P., MacMahon B. Oral contraceptive use: association with frequency of hospitalization and chronic disease risk indicators. Am J Public Health 1978, 68(4):335-341.
27. Bourque M., Dluzen D.E., Di Paolo T. Neuroprotective actions of sex steroids in Parkinson's disease. Front Neuroendocrinol 2009, 30(2):142-157.
28. Green P.S., Simpkins J.W. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 2000, 18(4-5):347-358.
29. Dluzen D.E., McDermott J.L., Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol Teratol 1996, 18(5):603-606.
30. Ascherio A., Chen H., Schwarzschild M.A., Zhang S.M., Colditz G.A., Speizer F.E. Caffeine, postmenopausal estrogen, and risk of Parkinson's disease. Neurology 2003, 60(5):790-795.
31. Marder K., Tang M.X., Alfaro B., Mejia H., Cote L., Jacobs D., et al. Postmenopausal estrogen use and Parkinson's disease with and without dementia. Neurology 1998, 50(4):1141-1143.
32. Simpson C.F., Boyd C.M., Carlson M.C., Griswold M.E., Guralnik J.M., Fried L.P. Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement. J Am Geriatr Soc 2004, 52(1):123-127.
33. Phillips N., Reay J., Martyn C. Validity of mortality data for Parkinson's disease. JEpidemiol Community Health 1999, 53:587-588.